74. 下垂体性PRL分泌亢進症 Prolactin secreting pituitary adenoma Clinical trials / Disease details
臨床試験数 : 18 / 薬物数 : 33 - (DrugBank : 10) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04107480 (ClinicalTrials.gov) | June 21, 2019 | 27/8/2019 | PRolaCT - Three Prolactinoma RCTs | PRolaCT - Three Multicenter Prolactinoma Randomized Clinical Trials | Prolactinoma;Prolactin-Producing Pituitary Tumor | Procedure: Endoscopic trans-sphenoidal adenoma resection;Drug: Dopamine Agonists | Leiden University Medical Center | NULL | Recruiting | 18 Years | N/A | All | 880 | Phase 4 | Netherlands |
| 2 | NCT03717454 (ClinicalTrials.gov) | December 1, 2018 | 14/10/2018 | Dopamine D2 Receptors(D2R) Imaging in Prolactinomas | The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas. | Prolactinoma | Other: Surgery;Drug: Drug treatment | Zhebao Wu | Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital | Not yet recruiting | 18 Years | 65 Years | All | 50 | N/A | NULL |
| 3 | NCT03038308 (ClinicalTrials.gov) | September 16, 2016 | 30/1/2017 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability | Hyperprolactinemia;Prolactinoma | Drug: Ropinirole | Columbia University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Active, not recruiting | 18 Years | 70 Years | All | 23 | Phase 1/Phase 2 | United States |
| 4 | NCT03353025 (ClinicalTrials.gov) | January 1, 2016 | 20/2/2017 | Study on Therapy of Non-invasive Prolactinoma | Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma | Prolactinoma | Procedure: transsphenoidal surgery treatment;Drug: dopamine agonist treatment | First Affiliated Hospital, Sun Yat-Sen University | NULL | Recruiting | 18 Years | 60 Years | All | 394 | N/A | China |
| 5 | NCT01620138 (ClinicalTrials.gov) | March 2010 | 18/9/2011 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist | Non-functioning Pituitary Adenomas;Prolactinomas | Drug: Pasireotide;Drug: cabergoline | Universidade Federal do Rio de Janeiro | NULL | Completed | 18 Years | N/A | All | 21 | Phase 2/Phase 3 | Brazil |